REGENERON PHARMACEUTICALS, INC. reported revenue of $4.29B for the period ended 2026-06-30, +16.7% year on year. Net income was $1.30B, a 30.2% net margin on a 100.0% gross margin. Free cash flow for the period was $0.52B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $4.29B | +16.7% |
| Gross profit | $4.29B | — |
| Operating income | $1.29B | — |
| Net income | $1.30B | -6.8% |
| Gross margin | 100.0% | Net margin 30.2% |
| Revenue Q/Q | +19.0% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| R&D | $1.63B | 38.0% |
| SG&A | $0.66B | 15.4% |
| Tax & other | $-0.00B | -0.1% |
| Item | Amount |
|---|---|
| Total assets | $41.73B |
| Total liabilities | $10.02B |
| Shareholders' equity | $31.71B |
| Equity / assets | 76.0% |
| Operating cash flow | $0.81B |
| Capital expenditure | $0.29B |
| Free cash flow | $0.52B |
| Cash conversion (OCF / net income) | 63% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
RF ・ RSG ・ RMD ・ RVTY ・ HOOD ・ ROK ・ ROL ・ ROP ・ ROST ・ RCL ・ SPGI ・ CRM
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies